Huang Chienhsiu, Lin Lichen, Kuo Sufang
Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
Department of Nursing, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
Antibiotics (Basel). 2024 Sep 23;13(9):907. doi: 10.3390/antibiotics13090907.
The addition of sulbactam restores the complete range of cefoperazone activity against bacteria and extends its spectrum of action to include the species. The effectiveness of cefoperazone/sulbactam against multiresistant has not been investigated. The purpose of the current meta-analysis was to compare the efficacy of cefoperazone/sulbactam-based therapeutic regimens and non-cefoperazone/sulbactam-based therapeutic regimens in the treatment of multiresistant infections. The current meta-analysis of 10 retrospective studies provides evidence that cefoperazone/sulbactam-based therapeutic regimens are superior to non-cefoperazone/sulbactam-based therapeutic regimens in terms of 30-day mortality and clinical improvement in patients with multiresistant infections. The risk of mortality was reduced by 38% among multiresistant infections in patients who received cefoperazone/sulbactam-based therapeutic regimens. The cefoperazone/sulbactam-based combination therapy was superior to the cefoperazone/sulbactam monotherapy in terms of 30-day mortality when both therapeutic regimens were compared to the tigecycline monotherapy in patients with multiresistant infections.
舒巴坦的加入恢复了头孢哌酮对细菌的完整活性范围，并将其抗菌谱扩展至包括[具体菌种]。头孢哌酮/舒巴坦对多重耐药菌的有效性尚未得到研究。本荟萃分析的目的是比较基于头孢哌酮/舒巴坦的治疗方案与非基于头孢哌酮/舒巴坦的治疗方案在治疗多重耐药菌感染中的疗效。目前对10项回顾性研究的荟萃分析提供了证据，表明在30天死亡率和多重耐药菌感染患者的临床改善方面，基于头孢哌酮/舒巴坦的治疗方案优于非基于头孢哌酮/舒巴坦的治疗方案。接受基于头孢哌酮/舒巴坦治疗方案的患者中，多重耐药菌感染的死亡率风险降低了38%。在多重耐药菌感染患者中，当将两种治疗方案与替加环素单药治疗进行比较时，基于头孢哌酮/舒巴坦的联合治疗在30天死亡率方面优于头孢哌酮/舒巴坦单药治疗。
